参考文献：
1) 報告書：田中純子、他：平成 21 年度　厚生労働科学研究費補助金　肝炎等克服緊急対策研究事業　肝炎状況・長期予後の疫学に関する研究　研究報告書, 2010; 11-14
2) Chen CJ, Yang HI, Su J, et al. JAMA 2006; 295: 65-67
3) Ikeda K, Saitoh S, Arase Y, et al. Hepatology 1999; 29: 1124-1130
4) Kasahara A, Hayashi N, Mochizuki K, et al. Hepatology 1998; 27: 1394-1402
5) Tseng TC, Liu CJ, Yang HC, et al. Gastroenterology 2012; 142: 1140-1149

英文要旨

A follow-up survey of hepatitis virus carriers after notification of their infection in Okayama prefecture

Sohji Nishina[1], Junko Kurihara[2], Toshiaki Noriyasu[2], Tatsuya Itoshima[3], Kazuhide Yamamoto[4], Junko Tanaka[5], Keisuke Hino[1]

In Okayama prefecture we investigated by questionnaires whether hepatitis B virus (HBV) (n=549) or hepatitis C virus (HCV) carriers (n=803) consulted a doctor after they had been informed of their infection at their initial checkup for viral hepatitis between 2002 and 2006. The ratio of patients who consulted a doctor after notification of infection was 38.4% (211/549) of HBV carriers and 49.4% (397/803) of HCV carriers, respectively. Among those patients, 53.1% of HBV carriers and 73.4% of HCV carriers were on follow care at the start of this investigation. These results indicated a need to establish a more effective follow up system for hepatitis virus carriers following notification at the initial medical checkup.

1) Department of Hepatology and Pancreatology, Kawasaki Medical School

2) Public Health Policy Division, Department of Health and Social Welfare, Okayama Prefectural Government

3) Okayama Prefectural Medical Association (Okayama Saiseikai General Hospital)

4) Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

5) Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima University, Institute of Biomedical and Health Sciences

Comprehensive miRNA Expression Analysis in Peripheral Blood Can Diagnose Liver Disease

Yoshiki Murakami[1]*, Hidenori Toyoda[2], Toshihito Tanahashi[3], Junko Tanaka[4], Takashi Kumada[2], Yusuke Yoshioka[5], Nobuyoshi Kosaka[5], Takahiro Ochiya[5], Y-h Taguchi[6]

1 Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan, 2 Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan, 3 Department of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan, 4 Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan, 5 Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan, 6 Department of Physics, Chuo University, Tokyo, Japan

Abstract

Background: miRNAs circulating in the blood in a cell-free form have been acknowledged for their potential as readily accessible disease markers. Presently, histological examination is the golden standard for diagnosing and grading liver disease, therefore non-invasive options are desirable. Here, we investigated if miRNA expression profile in exosome rich fractionated serum could be useful for determining the disease parameters in patients with chronic hepatitis C (CHC).

Methodology: Exosome rich fractionated RNA was extracted from the serum of 64 CHC and 24 controls with normal liver (NL). Extracted RNA was subjected to miRNA profiling by microarray and real-time qPCR analysis. The miRNA expression profiles from 4 chronic hepatitis B (CHB) and 12 non alcoholic steatohepatitis (NASH) patients were also established. The resulting miRNA expression was compared to the stage or grade of CHC determined by blood examination and histological inspection.

Principal Findings: miRNAs implicated in chronic liver disease and inflammation showed expression profiles that differed from those in NL and varied among the types and grades of liver diseases. Using the expression patterns of nine miRNAs, we classified CHC and NL with 96.59% accuracy. Additionally, we could link miRNA expression pattern with liver fibrosis stage and grade of liver inflammation in CHC. In particular, the miRNA expression pattern for early fibrotic stage differed greatly from that observed in high inflammation grades.

Conclusions: We demonstrated that miRNA expression pattern in exosome rich fractionated serum shows a high potential as a biomarker for diagnosing the grade and stage of liver diseases.

Introduction

MicroRNAs (miRNAs) are a gene family that is evolutionarily conserved and have important roles in the control of many biological processes, such as cellular development, differentiation, proliferation, apoptosis, and metabolism [1]. Aberrant expression of miRNAs in liver tissue has been implicated in the progression of liver fibrosis, and hepatocarcinogenesis [2,3,4]. Recently, two independent groups showed that miR-122 plays a critical role in the maintenance of liver homeostasis and anti-tumor formation [5,6].

Exosome in one of the endoplasmic reticulum carries mRNAs and miRNAs [7]. Recently, it has become clear that exosome perform intercellular signaling through miRNA. miRNAs are released through a ceramide-dependent secretory machinery and are then transferred and become functional in the recipient cells

[8]. In a prior study using human blood and cultured cells, several miRNAs were selectively packaged into microvesicle (MV) and actively secreted [9]. In another study, miRNAs originating from EBV was transported by exosome and then participated in the immune response of host cells [10]. In HCC cells as well, this type of exosome-mediated miRNA transfer is an important mechanism of intercellular communication [11].

It has also become clear that exosome can adjust to immune function, control infection or carry the virus itself. Exosomes of T, B and dendritic immune cells contain a repertoire of miRNAs that differ from that of their parent cells [12,13]. Exosomes released from nasopharyngeal carcinoma cells harboring latent EBV were shown to contain LMP1, signal transduction molecules, and virus-encoded miRNAs [14]. Retroviruses evade adaptive immune responses by using nonviral or host exosome biogenesis pathways to form infectious particles and as a mode of infection [15].

Recent evidence has shown that the expression patterns of serum or plasma miRNAs are altered in several diseases, in particular heart disease, sepsis, malignancies, and autoimmune diseases (reviewed in [16]). Discoveries such as this is encouraging and has propelled further research leading to the hypothesis that circulating miRNAs are detectable in serum and plasma in a form sufficiently stable to serve as biomarkers [17,18]. One such example is that tumour-associated miRNAs were found in the serum of diffuse large B-cell lymphoma patients [19]. In other examples, serum levels of miR-34a and miR-122 were associated with histological disease severity in patients with CHC or non-alcoholic fatty-liver disease (NAFLD) [20]. In fact, the serum level of miR-122 strongly correlates with serum ALT activity and with necro-inflammatory activity in patients with CHC and elevated ALT levels. However, there seems to be no significant correlation between fibrosis stage and functional capacity of the liver [21]. The expression levels of miR-122 and miR-194 correlated negatively with age in patients with CHB and HBV associated acute-on-chronic liver failure [22]. The expression level of miR-122 in serum was found to be closely related to non drug-induced acute liver injury [23]. Based on the above, it comes as no surprise that recently, the expression profile from extracellular miRNA is being used clinically to diagnose various diseases.

Here, in order to obtain data with high resolution that is reproducible, we extracted MVs from serum using exoquick and then performed a comprehensive microarray analysis. We attempted to diagnose HCV infection, and ascertain the degree of liver inflammation and fibrosis stage using exosome-rich fractioned miRNA. In short, we investigate if serum-derived miRNAs had the potential to serve as non-invasive bio-markers for various liver diseases.

Results

Reproducible Gene-analysis Using Microarray

In microarray experiments, serum analysis is comparatively easy; however, the downside is that the accuracy and reproducibility of the results are usually not satisfactory. To circumvent this drawback, we devised a procedure that would give us higher accuracy and reproducibility. Serum samples from NL subjects were prepared and divided into two groups; for the first, RNA was extracted using exoquick treated serum; and in the second, RNA was extracted from total serum. Next, miRNA expression was analyzed using Agilent miRNA microarray. The above procedure was performed independently twice (**Fig. 1A**). We compared the miRNA expression pattern among the four microarray results (**Fig. 1B**) and found that miRNA expression analysis using exoquick was the more reliable and reproducible (**Fig. 1C**).

Exosome from normal human prostatic cell lines PNT-2, was yielded by the conventional ultra-centrifugation method [8]. We prepared serums with and without exoquick treatment and performed immunoblot analysis with anti-CD63 (**Fig. 1D**). Bands of the expected relative sizes were detected in serum treated with exoquick. We designated RNA extracted using exoquick treated serum as exosome-rich fractionated RNA.

Unique Expression Pattern of miRNA in CHC

We attempted to diagnose CHC using the miRNA expression pattern found in the peripheral blood samples from 64 CHC and 24 NL. The expression of nine miRNAs (miR-1225-5p, miR-1275, miR-638, miR-762, miR-320c, miR-451, miR-1974, miR-1207-5p, and miR-1246) allowed us to categorize patients as CHC or NL with 96.59% accuracy (**Fig. 2, 3** Table 1 and Table S1). As shown in **Fig. 2C**, CHC and NL were well differentiated due to

their distinct miRNA expression patterns. The expression pattern of 12 miRNAs led to the distinction of CHC, CHB, NASH, and NL with 87.50% accuracy (**Fig. 4, S1A,** and Table S1). The accuracy of determining whether samples were CHC or CHB, CHC or NASH, CHB or NASH was 98.35%, 97.37%, and 87.50%, respectively. The accuracy of judging whether samples were NL or CHB, NL or NASH, was 89.29% and 88.89%, respectively (**Fig. 3, S1B** and Table S1). Unlike CHC and NL, there were relatively fewer analyses done of CHB and NASH (due to a small sample size), therefore, we used "*in silico*" resampling to overcome any possible bias. With "*in silico*" we found that it was highly reproducible to determine with high accuracy whether samples were CHC, CHB, NASH, or NL, CHC or CHB, CHC or NASH, CHC or NL, CHB or NASH, CHB or NL, or finally NASH or NL (**Fig. S2 to S8** and Supporting Information).

In order to validate our above-mentioned classifications, we prepared a separate independent sample consisting of 31 CHC, 16 CHB, and 8 NASH. We established miRNA expression patterns using microarray for each of these chronic liver disease groups. We tried to discriminate among the classifications in the independent cohort using the semi-supervised learning method [24] based only on the labels in the original sample group and the selected miRNAs shown in Table S1. The accuracy of judging whether samples were CHB or CHC, CHC or NASH, CHB or NASH, was 74.47%, 87.18%, and 79.19%, respectively (**Fig. S9**, Table 1, and Supporting Information). During the process of obtaining these results, we noticed that different versions of the Feature Extraction (FE) Software provided slightly different results, however it was not possible to fully unify these versions of FE. This may explain the relatively lower performance of the independent group compared with the original samples that mostly used the same FE Software versions.

miRNA Expression Correlates with the Grade of Liver Inflammation

The grade of inflammation for CHC patients was ascertained by liver histological examination, and then samples were divided into four groups A0, A1, A2, and A3 based on their fibrosis stage. miRNA expression profiles were then established for CHC according to each of their inflammation grade. From the four groups (A0 to A3), a combination of six arbitrary pairs is possible. miRNAs which had significant differential expression in five or more of the six pairs were extracted (p<0.05). Five miRNAs (miR-1914*, miR-193a-5p, miR-22, miR-659, and miR-711) had expression levels that increased as the severity of liver inflammation progressed. On the other hand, the expression levels of nine miRNAs (miR-1274b, miR-197, miR-1974, miR-21, miR-34a, miR-451, miR-548d-5p, miR-760, and miR-767-3p) significantly decreased with the progression of liver inflammation (**Fig. 5, S10** and Table S2).

The Grade of Liver Fibrosis Corresponded with the Expression Level of miRNAs

As previously noted, CHC samples were divided into F0, F1, F2, and F3 based on patients' fibrotic stage. From these four fibrotic groups, a combination of six arbitrary pairs were possible. miRNAs that had significant differential expression in all six pairs were extracted (p<0.05). The expression levels of two miRNAs (miR-483-5p and miR-671-5p) significantly increased the higher the fibrotic stage and the expression level of 14 miRNAs (let-7a, miR-106b, miR-1274a, miR-130b, miR-140-3p, miR-151-3p, miR-181a, miR-19b, miR-21, miR-24, miR-375, miR-548l, miR-93, and miR-941) became progres-

A

serum

RNA from total serum 1st → RNA from exoquick treatment 1st → RNA from total serum 2nd → RNA from exoquick treatment 2nd

miRNA microarray analysis

total serum 1st → exoquick treatment 1st → total serum 2nd → exoquick treatment 2nd

B

C

	exoquick 1st	total serum 1st	exoquick 2nd	total serum 2nd
exoquick 1st	1	0.836	0.998	0.809
total serum 1st	−	1	0.831	0.930
exoquick 2nd	−	−	1	0.821
total serum 2nd	−	−	−	1

D

Serum

PNT-2   -EQ   +EQ

CD63

Figure 1. The method used to obtain reproducible data for microarray analysis conducted on serum-extracted samples. A. NL patients' serum were sampled twice. In the first, RNA was extracted first from untreated serum, and then extracted again from serum treated with exoquick. In the second serum sample, RNA was also extracted from both untreated serum and serum treated with exoquick. Microarray analysis was conducted for RNA in a total of four samples. B. Reproducibility test of microarray data. Scatter plots comparing non- normalized signal intensities of miRNAs in two independent experiments from human total serum and exosome rich fraction. Red and black denotes high and low miRNA expressions respectively. Total serum extracted first, versus exosome rich fraction first (left), total serum extracted first versus second (middle), and exosome rich fraction extracted first versus second (right). C. Pearson's pairwise correlations of signal intensities of miRNAs from human total serum and exosome rich fraction. D. Western blot was performed for untreated serum, serum extracted by exoquick and exosome fraction from PNT-2, using anti-CD63.
doi:10.1371/journal.pone.0048366.g001

A

B

prediction		result	
		CHC	NL
	CHC	64	3
	NL	0	21

accuracy 96.6%

C

O :CHC   O :NL

sively downregulated as liver fibrotic stage increased (**Fig. 6, S11** and Table S2).

Classification of Liver Inflammation Grade and Fibrotic Stage Using miRNA Expression Pattern

We attempted to classify liver inflammation grade and fibrosis stage using miRNA expression pattern. Liver inflammation was diagnosed by Leave One Out Cross-Validation (LOOCV); the accuracy of determining A1 from other inflammation grade was 71.88% and its odds ratio was 7.08. The accuracy of determining A2 and A3 was 75.00% and 82.81%, and their odds ratios were 9.50 and 11.08, respectively. In our study, we were unable to accurately classify A0 because we were limited to only one sample for that grade (**Fig. 7A**). Diagnosis of liver fibrosis by LOOCV showed that determining F0 from the other fibrotic stages had an accuracy of 87.50% and an odds ratio of 14.25. The classification of F1, F2, and F3 had accuracy rates of 65.63%, 70.31%, and 73.44% and odds ratio of 3.16, 6.39 and 5.80, respectively (**Fig. 7B**).

miRNA Expression Level Detected by Real-time qPCR Validated the Microarray Result

Four miRNAs (miR-1207-5p, miR-134, miR-1249, and miR-1183) with expression levels that differed among liver inflammation grades and liver fibrotic stages were chosen in order to confirm the microarray results using stem-loop based real-time qPCR. miRNAs that correlated with other clinical characteristics besides liver fibrosis and inflammation were listed using the Wilcoxon test. We performed two Wilcoxon tests and ranked miRNAs based on their p-value from smallest to largest and selected the miRNAs with the four smallest p-values that were common among the two Wilcoxon tests.

The real-time qPCR result was consistent with the microarray analysis (**Fig. 8**). Here also, we applied "*in silico*" resampling to compensate for the small number of patients used in the real-time qPCR analysis. The results of the "*in silico*" resampling conferred with the results of the real-time qPCR (**Fig. S12**).

miRNA Expression Pattern was Closely Related to Several Clinical Parameters in CHC

Although we observed that miRNA expression correlated with ALT value, we were unable to identify miRNAs that displayed a strong correlation. 12 miRNAs were chosen sequentially from miRNAs with a high absolute correlation coefficient. One to 12 of these selected miRNAs were used to compare the canonical correlation coefficient of the above. When the expression patterns of six of the 12 miRNAs were compared with serum ALT value, the correlation coefficient and p-value were 0.44 and 4.91E−02, respectively. Similarly, when serum Albumin value was compared with the expression pattern of all 12 miRNAs, the correlation coefficient and p-value were 0.59 and 2.04E−02, respectively. Finally when the amount of serum HCVRNA was compared with the expression pattern of 12 miRNAs, the resulting correlation coefficient and p-value were 0.59 and 1.89E−02, respectively (**Fig. 9, S13** and Table S3).

Expression Pattern of a Several miRNAs Correlated to Serum and Hepatic Tissue

In a previous report, we described the miRNA expression pattern found in liver tissues obtained from 105 CHC [2]. From this group, we analyzed the miRNA expression of hepatic tissue and serum in 60 samples. We observed that the expression pattern of three miRNAs (miR-134, miR-200b, miR-324-5p) in hepatic tissue negatively correlated with that in serum, and the expression pattern of miR-370 in hepatic tissue positively correlated with that in serum (p<0.05) (Table S4). However, there was no significant correlation between the expression pattern of miR-122 in the hepatic tissue and serum (**Fig. S14** and Table S4).

Discussion

In this comprehensive miRNA analysis in various chronic liver diseases, we observed that aberrant expression of miRNAs was closely related to disease progression. Based on this, we believe that these miRNAs are potential readily accessible biomarkers, useful for diagnosing hepatic viral infection and for grading or staging liver diseases.

Many investigators have elected to use miRNA from serum instead of miRNA from exosome as the candidate for diagnosing diseases [18,20,22,25,26]. In our study, when exoquick was used, exosome could not be isolated therefore other MVs similar in size to exosome were also extracted. In other words, exoquick not only collected miRNAs contained in exosome, but also miRNA that were or were not combined with protein. Despite this, we found that exoquick delivered results that were superior to those obtained without exoquick. Therefore, although the process of analyzing miRNA from serum is simple, we chose to analyze miRNA from exosome rich fraction since it has a higher rate of reproducibility. Moreover, since exosome is closely related to intercellular signaling [14,27], it is expected that data obtained by exosome analysis can clarify the mechanism of chronic infection and inflammation [28].

When we extended our analysis from miR-122 to all miRNAs, it became clear that the expression level of several miRNAs correlated with the progression of liver fibrosis. In fact, recent studies have stated that when the expression levels of adequate numbers of miRNAs is used to identify disease, diagnostic ability is significantly higher than using a single miRNA [29]. In this study, when liver fibrosis was diagnosed using miRNA expression, distinguishing between F0 and F1-3 was done with 87.50% accuracy. Since F0 cannot be distinguished from other stages of chronic liver disease using blood examination, we propose that using miRNA expression pattern may be useful for diagnosing chronic liver disease that is in the early stage.

Previous studies have shown that the level of miR-122 in blood plasma increased earlier than in ALT in the presence of toxic liver injury in rodents [30]. Serum levels of miR-122 in patients with CHC are frequently elevated compared with healthy individuals [21]. Bihrer et al. mentioned that variations in the concentration of miR-122 in serum or plasma tend to be more specific for liver diseases than ALT and AST. This is because miR-122 is almost exclusively expressed in the liver, whereas ALT and AST originate from skeletal muscles and other tissues, therefore their diagnostic value is low [31]. In our study, the expression level of miR-122 had

Figure 3. Pairwise heatmap of the miRNAs used for classifying two arbitrary groups. Pairwise heatmap showed the miRNAs and their p-value of two arbitrary groups.
doi:10.1371/journal.pone.0048366.g003

Figure 4. Pairwise heatmap of the miRNAs used for classifying among four groups.
doi:10.1371/journal.pone.0048366.g004

a significant positive correlation with the grade of liver inflammation, serum albumin value, or serum HCVRNA value. However, miR-122 expression did not significantly correlate with liver fibrosis stage. Moreover, there was no correlation between the expression level of miR-122 in liver tissue, and that in serum in the same 60 samples (**Fig. S14**). The expression pattern of only four miRNAs out of total liver tissue miRNAs correlated with the expression patterns of miRNA found in the serum (Table S4). Most serum miRNA had expression patterns that differed from those observed in hepatic tissue samples. Moreover, we observed differences in miRNAs expression between various tissues [32]. These differences were observed even in tissues taken from the same subject; at present we are unclear as to the reason for this phenomenon.

In regards to the progression of liver fibrosis and the expression pattern of miR-21, previous studies concur with our result that miR-21 expression level significantly decreased in response to the progression of liver fibrosis [20]. Taken together, this suggests that any miRNAs that may have been emitted from liver tissue cannot be detected in serum after hepatic cell injury.

The expression pattern of many miRNAs in serum positively correlated with serum ALT, albumin, and HCVRNA levels in this study (**Fig. 9, S13** and Table S3). This result contradicts prior assumptions that no correlation exists between serum miR-122 and HCVRNA serum levels [21]. Three likely reasons for this difference in results are: 1) the detection method used (real-time qPCR versus microarray), 2) the difference in the subjects' ages (the subjects in this study were older), and 3) the difference in the amount of miRNAs (multiple miRNAs vs. a single miRNA) used to identify the clinical parameters of the disease.

CHC and NL were classified with a high level of accuracy using the expression pattern of miRNA. In order to elucidate if the miRNA expression in CHC is common to other chronic liver diseases including CHB, we compared the miRNA expression pattern of CHC with those of NASH and CHB. The result of this analysis was that CHC could be clearly distinguished from both CHB and NASH. These results demonstrate that the varying forms of chronic liver disease have their own unique miRNA expression pattern. NASH is a histological diagnosis that rests on a combination of features and can only be confirmed by liver biopsy. Recently, NASH was diagnosed by first determining the existence of NAFLD from blood samples and then performing an ultrasound tomography. Finally, liver fibrosis stage was determined by Fibroscan

Table 1. Characteristics of subjects in this study of original samples and independent samples.

Original samples

Characteristics	CHC	CHB	NASH	NL
Gender	F: 34/M: 30	F: 2/M: 2	F: 3/M: 9	F:11/M: 13
Age (years)	59.5±8.3	46.8±14.5	52.3±13.1	50.8±12.0
AST (IU/L)	50.1±29.8	83.3±53.7	46.2±16.0	N.D
ALT (IU/L)	57.6±40.6	167.8±170.3	74.5±34.9	N.D
WBC (x10³/mm³)	5.1±1.5	4.7±1.5	6.2±1.6	N.D
Platelet (x10⁴/mm³)	16.6±5.9	14.8±6.3	24.7±8.0	N.D
Total Bilirubin (mg/dl)	0.65±0.22	0.83±0.40	0.76±0.25	N.D
Weight (kg)	57.9±9.18	58.8±4.3	74.9±24.8	59.6±9.6
ALP (IU/L)	267.0±88.4	223.3±25.0	232.7±36.2	N.D
γGTP (IU/L)	46.9±42.3	77.3±82.2	58.4±20.9	N.D
Hemoglobin (g/dl)	13.8±1.2	14.5±0.59	14.7±1.6	N.D
Albumin (g/dl)	4.1±0.4	4.2±0.5	4.4±0.3	N.D

Independent samples

Characteristics	CHC	CHB	NASH
Gender	F: 18/M: 13	F: 10/M: 6	F: 6/M: 2
Age (years)	59.5±8.3	46.8±14.5	54.8±12.7
AST (IU/L)	50.1±29.8	83.3±53.7	80.9±50.0
ALT (IU/L)	57.6±40.6	167.8±170.3	108.9±76.2
WBC (x10³/mm³)	5.1±1.5	4.7±1.5	5.5±1.8
Platelet (x10⁴/mm³)	16.6±5.9	14.8±6.3	19.3±7.6
Total Bilirubin (mg/dl)	0.65±0.22	0.83±0.40	0.73±0.25
Weight (kg)	57.9±9.18	58.8±4.3	66.4±9.9
ALP (IU/L)	267.0±88.4	223.3±25.0	278.6±100.6
γGTP (IU/L)	46.9±42.3	77.3±82.2	130.1±81.23
Hemoglobin (g/dl)	13.8±1.2	14.5±0.59	13.6±1.4
Albumin (g/dl)	4.1±0.4	4.2±0.5	3.8±0.3

Abbreviations; CHC, chronic hepatitis C; CHB, chronic hepatitis B; NASH, non alcoholic steatohepatitis; NL, normal liver (healthy control); N.D, no data.
doi:10.1371/journal.pone.0048366.t001

(reviewed in [33]). However, when the results of these and other measures fail to yield a diagnosis then a pathology evaluation is necessary. Using "*in silico*" resampling to increase the reliability of our data, has led us to believe that NASH diagnosis may be possibly through blood examination.

We tested the reliability of our analysis in two ways and obtained reproducible results in both cases. First we enrolled an independent sample group, and second, we created virtual cohorts using in silico resampling to overcome our small sample size.

In this study we concluded that miRNA profiling is a promising alternative to diagnosing liver disease. This is based on our demonstration that the following evaluations could be performed using suitable miRNA expression profiles (1) determining the stage or grade of chronic liver disease, (2) ascertaining the clinical status of chronic liver diseases, and (3) distinguishing among various forms of chronic liver diseases. While these results suggest there is great potential and benefit of

miRNA profiling, future studies in a larger population of CHC patients are warranted to fully elucidate the diagnostic potential of serum miRNA expression.

Materials and Methods

Patient Selection

A cohort of 64 CHC, 4 CHB, and 12 NASH patients who had undergone liver biopsy, as well as 24 healthy control subjects was enrolled. We also prepared independent samples consisting of 31 CHC, 12 CHB, and 8 NASH to validate our results. Patient characteristics are summarized in Table 1 and detailed clinical data is depicted in Table S5. The criteria for exclusion for CHC, CHB, and NASH were: co-infection with human immunodeficiency virus (HIV) types 1 and 2, decompensated liver disease, organ transplantation, immune suppression, autoimmune disorders, consumption of >20 g/day alcohol, and past history of intravenous drug abuse. Healthy controls were selected if they were not infected with HBV, HCV, nor HIV, had normal liver function tests, and had no history of liver disease.

All patients or their guardians provided written informed consent, and Ogaki Municipal Hospital and Kyoto University Graduate School and Faculty of Medicine's Ethics Committee approved all aspects of this study in accordance with the Helsinki Declaration.

Liver Histology and Blood Examination

A liver biopsy specimen was collected from each patient before anti-viral treatment. Histological grading and staging of CHC liver biopsy specimens were performed according to the Metavir classification system [34]. NASH was diagnosed histologically [35].

Serum HCV RNA was quantified before IFN treatment using Amplicor-HCV Monitor Assay (Roche Molecular Diagnostics Co., Tokyo, Japan), while serum HBV DNA was quantified before treatment using Amplicor HBV Monitor Assay (Roche). Pretreatment blood tests were conducted to determine each patient's level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, gamma-glutamyl transpeptidase, white blood cell (WBC), platelets, and hemoglobin.

Blood Sampling

Peripheral blood was collected from all subjects directly into serum tubes before anti-viral treatment. The tubes were centrifuged at 1,500 g for 10 min at 4°C, sera were aliquoted and additionally centrifuged at 2,000 g to completely remove any remaining cells. Sera were stored at −80°C until use.

RNA Preparation

Total RNA from 200 ul of serum was prepared using miRNeasy mini kit (Qiagen, Hilden Germany) according to the manufacturer's instruction. Exosome rich fractionated RNA was prepared using Exoquick (System Biosciences, CA, USA). Briefly, 900 ul of serum was mixed with 250 ul of Exoquick and incubated for 12 hr at 4°C. The tubes were centrifuged at 1500 g for 30 min at room temperature and then supernatant was discarded. The pellet was dissolved with 200 ul of PBS with vigorous vortex. RNA was extracted using miRNeasy mini kit (Qiagen).

Immunoblot Analysis and Exosome Preparation

The procedure for exosome preparation has been previously described [8]. SDS-PAGE gels, SuperSep Ace 5–20% (194–15021) (Wako, Osaka, Japan), were calibrated with Precision Plus Protein Standards (161–0375) (Bio-Rad), and anti-CD63 (1:200)

Figure 5. Significantly differentially expressed miRNAs according to liver inflammation grade. Pairwise heatmap showing the miRNAs and p-value of two arbitrary grades.
doi:10.1371/journal.pone.0048366.g005

was used as primary antibodies. The dilution ratio of each antibody is indicated in parentheses. Two secondary antibodies (peroxidase-labeled anti-mouse and anti-rabbit antibodies) were used at a dilution of 1:5000. Bound antibodies were visualized by chemiluminescence using the ImmunoStar LD (Wako) and luminescent images were analyzed by a LuminoImager (LAS-3000; Fuji Film, Inc.). Only gels for CD63 (BD, NJ, USA) detection were run under non-reducing conditions. To exclude the

albumin and IgG in serum, Albumin & IgG Depletion SpinTrap kit was used (GE health care, WI, USA). After aliquots isolation, exosome-contained fraction was isolated by Exoquick according to standard instructions.

miRNA Microarray

To detect serum miRNA, 60 ng of RNA was labeled and hybridized using the Human microRNA Microarray Kit (Rel

Figure 6. Significantly differentially expressed miRNA according to liver fibrotic stage. Pairwise heatmap showing the miRNAs and p-value of two arbitrary stages.
doi:10.1371/journal.pone.0048366.g006

14.0) (Agilent Technologies, CA, USA) according to the manufacturer's protocol (protocol for use with Agilent microRNA microarrays Version 1.0). Hybridization signals were detected with a DNA microarray scanner G2505B (Agilent Technologies) and the scanned images were analyzed using Agilent feature extraction software (v9.5.3.1). We used raw data (gProcessedSignal) and normalized each expression so as to have zero mean and unit sample variance. The data presented in this manuscript have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series access number GSE33857: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE33857.

Real-time qPCR for Human miRNA

To detect miRNA expression level by real-time qPCR, TaqMan® microRNA assay (Applied Biosystems) was used to quantify the relative expression levels of miR-1207-5p (assay ID. 241060), miR-134 (assay ID. 000459), miR-1183 (assay ID. 002841), and miR-1249 (assay ID. 002868). The expression level of miR-16 (assay ID. 000391) was also measured and used as an internal control. cDNA was synthesized using the Taqman miRNA RT Kit (Applied Biosystems). RNA (2 ng/ml) in 5 ml of nuclease free water was added to 3 ml of 5 × RT primer, 10×1.5 μl of reverse transcriptase buffer, 0.15 μl of 100 mM dNTP, 0.19 μl of RNase inhibitor, 4.16 μl of nuclease free water, and 50 U of reverse transcriptase in a total volume of 15 μl. The reaction was performed for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C.

A

A1   A0+A2+A3

A1 vs A0+A2+A3	
accuracy	71.88%
Fisher's exact test	p-value: 4.07E-04
odds ratio	7.08

prediction		result	
		F	T
	F	22	12
	T	6	24

A2   A0+A1+A3

A2 vs A0+A1+A3	
accuracy	75.00%
Fisher's exact test	p-value:2.26E-04
odds ratio	9.50

prediction		result	
		F	T
	F	34	4
	T	12	14

A3   A0+A1+A2

A3 vs A0+A1+A2	
accuracy	82.81%
Fisher's exact test	p-value: 2.30E-03
odds ratio	11.08

prediction		result	
		F	T
	F	47	3
	T	8	6

B

F0   F1+F2+F3

F0 vs F1+F2+F3	
accuracy	87.50%
Fisher's exact test	p-value: 4.95E-02
odds ratio	14.25

prediction		result	
		F	T
	F	54	1
	T	7	2

F1   F0+F2+F3

F1 vs F0+F2+F3	
accuracy	64.62%
Fisher's exact test	p-value: 2.73E-02
odds ratio	3.16

prediction		result	
		F	T
	F	21	13
	T	10	20

F2   F0+F1+F3

F2 vs F0+F1+F3	
accuracy	70.31%
Fisher's exact test	p-value: 3.24E-03
odds ratio	6.39

prediction		result	
		F	T
	F	33	4
	T	15	12

F3   F0+F1+F2

F3 vs F0+F1+F2	
accuracy	73.44%
Fisher's exact test	p-value: 1.35E-02
odds ratio	5.80

prediction		result	
		F	T
	F	39	4
	T	13	8

Figure 7. Determining liver inflammation grade and fibrotic stage using miRNA expression pattern in LOOCV analysis. A. In order to diagnose the grade of liver inflammation, A0 was identified first. Next A1, A2, and A3 were identified in a similar manner as A0. For each, the accuracy rate, P value, and the odds ratio are shown. B. For liver fibrosis stage, F0 was first diagnosed following which the other stages F1, F2, and F3 were diagnosed in a similar manner. For each group the accuracy rate, P value, and the odds ratio are shown.
doi:10.1371/journal.pone.0048366.g007

Figure 8. Real-time qPCR validation of microarray analysis. The microarray expression analysis result of four miRNAs was reproduced in real-time PCR analysis. The pairs with p<0.001 are marked by "***".
doi:10.1371/journal.pone.0048366.g008

All reactions were run in triplicate. Chromo 4 detector (Bio-rad) was used to detect miRNA expression. To allow for the validation of microarray results with C(t) obtained by qPCR, raw gene expressions were transformed into logarithmic values. P-values were computed via one-sided t test. No averages over probes were taken for the microarray. The above procedures were also done with various packages/functions implemented in R (http://www.r-project.org/).

Statistical Analysis

For symptoms having discrete values, grade pairs were compared with Wilcoxon rank sum test (one-sided); otherwise, P-values were computed from correlation coefficients. In both cases, false discovery rate (FDR) of less then 0.05 computed from the P-value was regarded as significant. Benjamini and Hochberg criterion was used for FDR estimation. All p-values shown are significant even though they are raw numbers. No average over probes was taken before correlation analyses.

The Canonical Correlation Coefficients for miRNA Expression and Clinical Parameters

The canonical correlation coefficients were computed for ALT-miRNA, albumin-miRNA, and HCVRNA-miRNA correlations, using up to 12 miRNA with larger correlation coefficients (see Supporting Information).

Classification Analyses for Liver Fibrosis/inflammation

P-values were computed via one-sided t test using the raw expression values of each miRNA from the samples of CHC

and healthy controls. The logarithm of obtained P-values was then transformed into principal components scores via principal components analysis. Following this, grades were discriminated by linear discriminant analysis of CHC ages and the optimal number of principal components.

Selection of miRNAs Required to Diagnose Several Liver Diseases

For specific pairs consisting of one liver disease and a healthy control, their normalized miRNAs expression was transformed into principal components scores via principal components analysis. miRNAs having the larger first and second principal component scores were selected. Following this, the principal component scores of each sample was computed based solely on the selected miRNA expressions. Liver diseases were classified using the optimal number of these principal component scores.

In order to compensate for the relative small number of NASH and CHB patients, we performed "*in silico*" patients resampling analysis of the microarray data (see Supporting Information). All the above procedures were done with various packages/functions implemented in R.

"In silico" Resampling

"*In silico*" resampling is a tool often used to overcome the limitation of a small sample size. Using this technique, we combined the clinical traits of existing patients and created various virtual samples. Using these virtual cohorts, we were then able to increase the sample size (see Supporting information).

Figure 9. The list of miRNAs used to obtain the maximum correlation coefficient between miRNA expression level, and clinical characteristics. Pairwise heatmap showing miRNAs and their correlation coefficient and p-values.
doi:10.1371/journal.pone.0048366.g009

In order to validate the "*in silico*" resampling results, we prepared another sample set and once again performed "*in silico*" resampling using the microarray data from 99 CHC liver tissue samples [36]. The results proved that "*in silico*" resampling can accurately reproduce an entire population using only a small number of existing samples (see Supporting Information).

Reproducibility Test of Microarray Data

Data were analyzed using the GeneSpring GX10.0.2 (Agilent). Quality control (QC) was applied according to the manufacturer's instructions, and all data were approved by GeneSpring. Following Agilent recommendations, no inter-array normalization was applied because the similarity in miRNA expression among sample arrays was unknown [37]. Scatter plots and Pearson's pairwise correlations were performed with GeneSpring.

Supporting Information

Figure S1 Expression patterns of miRNAs used for discriminating among CHC, NL, CHB, and NASH. Classifying CHC, NL, CHB, and NASH using LOOCV. Distinguishing between two arbitrary groups using LOOCV.
(TIF)

Figure S2 Expression patterns of miRNAs used to discriminate among CHC, CHB, NASH, and NL "in silico" resampling for disease discriminant studies reflected by BMI. A. Box plots of expression pattern of the miRNAs used to discriminate among CHC, CHB, NASH, and NL. B. Discriminating among four groups using LOOCV. Accuracy is 95.25%. C. Two dimensional embedding of CHC, CHB, NASH, and NL by the first and second principle component scores computed with 12 selected miRNAs
(TIF)

Figure S3 The same as Fig.3 for CHC and CHB. A. Box plot of 19 miRNAs used for the discrimination. B. Classification between CHC and CHB. Accuracy is 100%. C. The two dimensional embedding of CHB and CHC by the first and second principal component scores computed with19 selected miRNAs.
(TIF)

Figure S4 The same as Fig.S3 for CHC and NASH. A. Box plots of 20 miRNAs used for the discrimination. B. Classification between CHC and NASH. Accuracy is 100%. C. Two dimensional embedding of CHC and NASH by the first and second principal component scores computed with 19 selected miRNAs
(TIF)

Figure S5 The same as Fig.S3 for CHC and NL. A. Box plots of 9 miRNAs used for the discrimination. B. Classification between CHC and NL. Accuracy is 100%. C. Two dimensional embedding of CHC and NL by the first and second principal component scores computed with 9 selected miRNAs
(TIF)

Figure S6 The same as Fig.S3 for CHB and NL. A. Box plots of 4 miRNAs used for the discrimination. B. Classification between CHB and NL. Accuracy is 93.5%. C. Two dimensional embedding of CHB and NL by the first and second principal component scores computed with 4 selected miRNAs
(TIF)

Figure S7 The same as Fig.S3 for NASH and NL. A. Box plots of 5 miRNAs used for the discrimination. B. Distinguishing between NASH and NL with 84.0% accuracy. C. Two

dimensional embedding of NASH and NL by the first and second principal component scores computed with 5 selected miRNAs
(TIF)

Figure S8 The same as Fig.S3 for CHB and NASH pair. A. Box plots of 17 miRNAs used for the discrimination. B. Distinguishing between CHB and NASH with 80.0% accuracy. C. Two dimensional embedding of CHB and NASH by the first and second principal component scores computed with 17 selected miRNAs
(TIF)

Figure S9 Classification of the independent sample using semi-supervised learning based on the labels in the original cohort. A. Classifying CHB and CHC. Accuracy is 74.47%. B. Classifying CHC and NASH. Accuracy is 87.18%. C. Classifying CHB and NASH. Accuracy is 79.19%.
(TIF)

Figure S10 miRNA expression pattern that correlated with the changes in clinical background. miRNAs that were differentially expressed according to the grade of liver inflammation
(TIF)

Figure S11 miRNA expression pattern that correlated with the changes in clinical background. miRNAs that were differentially expressed according to liver fibrosis stage
(TIF)

Figure S12 Real-time qPCR validation of microarray analysis "in silico" resampling for disease discrimination studies reflected by BMI. The result of microarray expression analysis of four miRNAs was reproduced using real-time PCR analysis. Pairs with $p < 0.001$ are marked by "***".
(TIF)

Figure S13 The relationship between the expression levels of several miRNAs and serum ALT, albumin, HCVRNA, respectively. Horizontal axis shows the number of miRNAs used in the analysis. Vertical axis shows the correlation index and p-values.
(TIF)

Figure S14 Summary of the relationship between the expression level of miR-122 and several clinical features. A. Expression level of miR-122 positively correlated with an increase in liver inflammatory grade. Asterisk denotes significant differences of $p < 0.05$. B. Expression level of miR-122 positively correlated with the serum level of albumin. C. Expression level of miR-122 positively correlated with the amount of serum HCVRNA. D. Expression level of miR-122 in exosome rich fraction did not significantly correlate with that in liver tissues.
(TIF)

Table S1 The list of miRNAs used for classifying arbitrary 2 groups and 4 groups, and their p-values.
(DOCX)

Table S2 Significantly differentially expressed miRNAs according liver inflammation grade and liver fibrotic stage.
(DOCX)

Table S3 The list of miRNAs used to obtain the maximum correlation coefficient between expression level of miRNAs, and clinical characteristics.
(DOCX)

Table S4 List of miRNAs with expression that corresponded in liver tissue and serum.
(DOCX)

Table S5 Clinical background of original samples and independent samples in detail.
(DOCX)

Table S6 Accuracy of LDA for "in silico" resampling.
(DOCX)

Author Contributions

Conceived and designed the experiments: YM NK TO YT. Performed the experiments: YM HT TT YY NK. Analyzed the data: TT YT. Contributed reagents/materials/analysis tools: HT JT TK. Wrote the paper: YM NK TO.

References

1. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
2. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, et al. (2011) The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 6: e16081.
3. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537–2545.
4. Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. Semin Oncol 38: 752–763.
5. Hsu SH, Wang B, Kota J, Yu J, Costinean S, et al. (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122: 2871–2883.
6. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, et al. (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122: 2884–2897.
7. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654–659.
8. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285: 17442–17452.
9. Zhang Y, Liu D, Chen X, Li J, Li L, et al. (2010) Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 39: 133–144.
10. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, et al. (2010) Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A 107: 6328–6333.
11. Kogure T, Lin WL, Yan IK, Braconi C, Patel T (2011) Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 54: 1237–1248.
12. Thery C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581–593.
13. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, et al. (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2: 282.
14. Meckes DG Jr, Shair KH, Marquitz AR, Kung CP, Edwards RH, et al. (2010) Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A 107: 20370–20375.
15. Gould SJ, Booth AM, Hildreth JE (2003) The Trojan exosome hypothesis. Proc Natl Acad Sci U S A 100: 10592–10597.
16. Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087–2092.
17. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513–10518.
18. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997–1006.
19. Lawrie CH (2007) MicroRNAs and haematology: small molecules, big function. Br J Haematol 137: 503–512.
20. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6: e23937.
21. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, et al. (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106: 1663–1669.
22. Ji F, Yang B, Peng X, Ding H, You H, et al. (2011) Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 18: e242–251.
23. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, et al. (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54: 1767–1776.
24. Chapelle O, Scholkopf B, Zien A (2006) Semi-supervised learning. Cambridge, Mass.: MIT Press. x, 508 p. p.
25. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
26. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, et al. (2010) Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 90: 1727–1736.
27. Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles important in intercellular communication. J Proteomics 73: 1907–1920.
28. Simons M, Raposo G (2009) Exosomes–vesicular carriers for intercellular communication. Curr Opin Cell Biol 21: 575–581.
29. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, et al. (2011) Toward the blood-borne miRNome of human diseases. Nat Methods 8: 841–843.
30. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al. (2009) Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55: 1977–1983.
31. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N (2005) Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 41: 380–382.
32. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401–1414.
33. Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33: 525–540.
34. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289–293.
35. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413–1419.
36. Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, et al. (2010) Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 3: 48.
37. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, et al. (2008) An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 10: 513–519.

Original Article

Follow up of the 987 blood donors found with hepatitis C virus infection over 9–18 years

Junko Matsuo,[1] Masaaki Mizui,[3] Hajime Okita,[3] Keiko Katayama,[1] Shiomi Aimitsu,[4] Tatsuro Sakata,[5] Makoto Obayashi,[6] Toshio Nakanishi,[7] Kazuaki Chayama,[2] Yuzo Miyakawa,[9] Hiroshi Yoshizawa[8] and Junko Tanaka[1] for the Hiroshima Hepatitis Study Group

[1]*Department of Epidemiology, Infectious Disease Control and Prevention,* [2]*Department of Medicine and Molecular Sciences, Graduate School of Biomedical Sciences, Hiroshima University,* [3]*Hiroshima Red Cross Blood Center,* [4]*Hiroshima Red Cross Hospital,* [5]*National Hospital Organization Fukuyama Medical Center,* [6]*Onomichi General Hospital,* [7]*Miyoshi Chuo Hospital, Hiroshima,* [8]*Hiroshima University, Hiroshima, and* [9]*Miyakawa Memorial Research Foundation, Tokyo, Japan*

Aim: To follow up blood donors found with hepatitis C virus (HCV) infection, to improve the outcome by antiviral treatments.

Methods: Between 1991 and 2001, 3377 of the 1 925 860 donors (0.18%) were found to have HCV infection at the Hiroshima Red Cross Blood Center in Japan. Of them, 987 were able to be followed regularly over 9–18 years until 2009, and received antiviral treatments as required.

Results: At the start, chronic hepatitis was diagnosed in 541 (54.8%), cirrhosis in five (0.5%) and hepatocellular carcinoma (HCC) in one (0.1%), whereas the remaining 439 (44.5%) had persistently normal aminotransferase levels (PNAL). Hospital visits were terminated voluntarily in 24.3% within the first year, 46.8% by 10 years and 50.9% by 17 years. Liver disease improved in 178 (18.0%), remained stable in 606 (61.4%) and aggravated in 170 (17.2%). Of the 541 donors with chronic

hepatitis, HCC developed in 28 (5.2%) and cirrhosis in 11 (2.0%), whereas HCV infection was cleared in 107 (19.8%) by antiviral treatments. In addition, HCV infection resolved in 54 of the 439 donors (12.3%) with PNAL after they had developed chronic hepatitis and received treatments. In donors with chronic hepatitis, the cumulative incidence of HCC was 4.1% at 10 years. By multivariate analysis, age and diagnosis of chronic hepatitis at the entry were found to be independent risk factors for the development of HCC.

Conclusion: Individuals with undiagnosed HCV infection need to be identified and receive medical care. They have to be motivated to merit from this health-care program.

Key words: alanine aminotransferase, chronic hepatitis C, hepatitis C virus, hepatocellular carcinoma, interferon, natural history

INTRODUCTION

OVER THE WORLD, an estimated 130–170 million people are infected with hepatitis C virus (HCV),[1] and most of them are unaware of their HCV infection. Because HCV infection evolves insidiously, it takes decades before overt liver disease develops, such as decompensated cirrhosis and hepatocellular carcinoma

(HCC).[2] Hence, it is necessary to identify individuals with undiagnosed HCV infection, and provide them with medical care for clearing HCV and preventing severe liver disease developing in them.

To make plans for management of individuals with undiagnosed HCV infection, it needs to be established to what extent liver disease has progressed in them, and how it advances over the long run, with or without medical interventions. Blood donation offers a unique opportunity to pursue such an undertaking, because it can identify HCV infections that have not been diagnosed previously.[3–9]

In 1991, when screening for antibody to HCV (anti-HCV) was introduced, a program was launched by the Hiroshima Hepatitis Study Group in Japan to identify HCV carriers at the blood donation. Liver disease was

diagnosed in the donors infected with HCV, so as to provide them with medical care to prevent the development of serious complications. Initially, 1019 blood donors with HCV infection were enrolled in the program, and the outcome was reported for 408 (40.0%) of them who had been followed for 5 years or longer by the year 2003.[10]

Here, we report the outcome of liver disease in 987 (96.9%) of them over 18 years of follow up. Various issues came up during the study, and they would need to be taken into consideration for improving health-care of the population with undiagnosed HCV infection hidden in the society. Further, the obtained results are hoped to lessen the national burden for management of hepatitis C that is expected to increase substantially in the foreseeable future.

METHODS

Study population

BETWEEN AUGUST 1991 and November 2001, 1 925 860 individuals wished to donate blood at the Japanese Red Cross (JRC) Hiroshima Blood Center, and 3377 (0.18%) were found to have HCV infection with high-titered anti-HCV and HCV RNA in the serum. They were informed of their HCV infection, and recommended to consult hepatology specialists in the 20 institutions constituting the Hiroshima Hepatitis Study Group: Hiroshima City Asa Hospital, Akitsu Prefectural Hospital, Hiroshima Prefectural Hospital, Kure City Medical Association Hospital, Kure Kyosai Hospital, Hiroshima University Hospital, KKR Hiroshima Kinen Hospital, Hiroshima City Hospital, Hiroshima Red Cross Hospital, Hiroshima General Hospital, Hiroshima JR Hospital, National Hospital Organization Kure Medical Center, National Hospital Organization Fukuyama Medical Center, Mitsubishi Mihara Hospital, Shobara Red Cross Hospital, Chugoku Rousai Hospital, Chuden Hospital, Nippon Kokan Fukuyama Hospital, Onomichi General Hospital and National Hospital Organization West Medical Center. Serving there as hepatology specialists were: Keiji Tsuji, M.D., Toshio Miura, M.D., Mikiya Kitamoto, M.D., Norihiko Katayama, M.D., Shuji Yamaguchi, M.D., Shoichi Tanakahshi, M.D., Hideaki Kodama, M.D., Yasuyuki Araki, M.D., Yasuyuki Aisaka, M.D., Kunio Ishida, M.D., Keitaro Yamashina, M.D., Hiroshi Kouno, M.D., Toshihiko Kaneyoshi, M.D., Kazushi Teramen, M.D., Kouji Kamada, M.D., Takashi Moriya, M.D., Hiroto Ishihara, M.D., Tomoo Yoshida, M.D., and Makoto Obayashi, M.D.

Of the 3377 donors infected with HCV, who were advised to undergo medical examination, 1097 (32.5%) visited liver clinics. The initial diagnosis was established in 1019 of them (30.2% of the total), and the date of initial visit, the date of birth and the baseline liver disease were filed in the computer. They were recommended to take regular check-ups, and receive antiviral treatment as required. The results of 408 carriers (40.0%), who had been followed for 5 years or longer, were reported in 2007.[10] Since then, they had been followed for an additional 6 years. The present study compiled all the data that had been accumulated on them over 18 years from 1991 to 2009, in an attempt to portray the outcome of undiagnosed HCV infection, and evaluate the efficacy of preventing liver disease by antiviral treatments. The 32 donors with normal aminotransferase levels at the initial diagnosis were excluded, because they visited clinics only once, and therefore the diagnosis of liver disease was not established in them. The remaining 987 donors entered the present study.

The study design conformed to the Declaration of Helsinki, and was approved by the Ethic Committees of Hiroshima University. Informed consent was obtained from each blood donor who was infected with HCV.

Data collection

A questionnaire form was distributed among hepatology specialists in the 20 institutions of the Hiroshima Hepatitis Study Group. They were asked to log the following: (i) initial diagnosis; (ii) compliance to regular visits; (iii) changes in liver disease over time; (iv) treatments with interferon (IFN); and (v) development of HCC. These data were made anonymous for the personal identification of any participant, and analyzed collectively.

Diagnosis of liver disease

Four clinical states were classified. They were: (i) persistently normal aminotransferase levels (PNAL); (ii) chronic hepatitis; (iii) cirrhosis; and (iv) HCC. PNAL was judged by: (i) values of alanine aminotransferase (ALT) within normal limits ($\leq$40 IU/L) twice or more within 6 months at least 2 months apart; (ii) normal platelet counts ($\geq$150 $\times$ 10^3/mm^3); (iii) lack of abnormal findings in those examined by imaging modalities; and (iv) no pathological findings in the liver biopsy for those who received it. Each attending specialist was asked his/her comprehensive opinion on the absence of liver disease in the HCV-infected donor with PNAL. The

diagnosis of chronic hepatitis, cirrhosis and HCC was left to the judgment of the attending hepatology specialist, who took into consideration the results of biochemical, imaging and other tests. The specialist made the decision as to whether his/her patient should receive IFN-based treatment or would better be followed regularly without treatment.

Markers of HCV infection

Hepatitis C virus RNA was determined by reverse-transcription polymerase chain reaction (RT–PCR) with primers deduced from conserved sequences in the 5'-non-coding region of the genome, irrespective of genotypes.[11] Genotypes of HCV were determined by RT–PCR with type-specific primers[12]

Genotypes of the interleukin 28B (*IL28B*) gene

The three donors who cleared HCV spontaneously were examined for *IL28B* genotypes.[13-15] The genomic DNA was extracted from the serum by RT–PCR, and polymorphisms of the *IL28B* gene at rs12979860 and rs8099917 were determined by the direct sequencing.

IFN-based treatments

Interferon was administrated according to the regular protocol at the discretion of the attending doctor and with the agreement of his/her patient. Types of IFN were natural IFN-α, recombinant IFN-α2 and -α2b until 2002. Natural IFN or recombinant IFN-α2a or -α2b at a daily dose of 6–9 million units (MU) was administrated during the initial 2 weeks, followed by 3 MU three times per week until 24 weeks after the start of IFN (total dose, 300–342 MU). After 2002, ribavirin was combined with recombinant IFN. After 2005, the standard-of-care therapy was implemented with pegylated-IFN-α2b (PEG-Intron; Shering Plough, Kenilworth, NJ) s.c. at a median dose of 1.5 μg/kg [range, 1.3–2.0 μg/kg]) once a week until 48 weeks, together with a daily dose of 600–1000 mg ribavirin (Rebetol [600–1000 mg]; Shering Plough) that was adjusted by the bodyweight. Sustained virological response (SVR) to IFN was diagnosed by the clearance of HCV RNA from serum 24 weeks after the treatment completion and thereafter.

Statistical analyses

Means and proportions were compared between groups by Student's *t*-test and χ^2-test or Fisher's exact test, respectively. For comparison of the frequency of the response to IFN (SVR and non-SVR) and the lack of IFN treatments in blood donors in whom liver disease was improved, unchanged and aggravated, post-hoc pairwise comparisons were carried out using the χ^2-test, and the *P*-value was adjusted by the method of Bonferroni. The Kaplan–Meier's life-table analysis and Cox proportional hazards models were employed in assessing the risk of developing chronic hepatitis or HCC with reference to sex, age and diagnosis at the entry, as well as the response to IFN-based treatments, utilizing JMP ver. 9 software (SAS Institute, Cary, NC, USA). All *P*-values were two-tailed, and those less than 0.05 were considered statistically significant.

RESULTS

Compliance with the follow up of blood donors who had HCV infection

FIGURE 1 ILLUSTRATES the compliance with follow up and shifting status of blood donors with HCV over 18 years. Notably, 24.3% of them were lost to follow up within the first year. Dropouts increased to 46.8% at 10 years and reached 51.6% at 15 years. Exclusive of the 52 blood donors, who entered the study in the first year and were followed for 18 years, only approximately 20% of donors with HCV infection complied with observation between 14 and 17 years. HCV was cleared in 17.4% of them over 17 years, including 8.3% who complied with observation and 9.1% who were lost to follow up.

Liver disease in the 987 blood donors with HCV infection

Clinical states of the 987 blood donors with HCV infection, at the time of donation, are summarized in Table 1. Cirrhosis had developed in five (0.5%) and HCC in one (0.1%) already. Chronic hepatitis was diagnosed in 541 (54.8%) of them, leaving only 439 donors (44.5%) who had PNAL. Acute hepatitis was diagnosed in a single donor infected with HCV-2a, who had been negative for HCV RNA at the previous donation. He developed chronic hepatitis 9 months later, and achieved SVR to antiviral treatment 1 year thereafter. Chronic hepatitis was more frequent in men than women (65.7% vs 45.2%, *P* < 0.001). Conversely, women possessed PNAL more often than men (54.4% vs 33.3%, *P* < 0.001). Liver biopsy was performed in